Laboratory staff need to be aware of the differences between individual thyroid function assays and the impact these can have on the monitoring of treatment for thyroid cancer and the detection of recurrent disease. Mark Stearman provides an overview of the current situation.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.